CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy
Source: Streetwise Reports  (7/11/19)
CVS Healthcare announced a $0.50/share quarterly dividend yesterday and got an added boost today as news spreads regarding easing of federal restrictions on pharmacy rebate plans. More >

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication
Source: Streetwise Reports  (7/10/19)
A study description and expected data readouts this year are provided in a ROTH Capital Partners report. More >

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'
Source: Streetwise Reports  (7/10/19)
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. More >

Sangamo and Pfizer Report Positive Results for Hemophilia A Study
Source: Streetwise Reports  (7/8/19)
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. More >

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'
Source: Streetwise Reports  (7/3/19)
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. More >

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress
Source: Streetwise Reports  (7/2/19)
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. More >

Bioasis Engages With the FDA: Here's What It Means
Source: Daniel Carlson for Streetwise Reports  (7/2/19)
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. More >

Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics
Source: Streetwise Reports  (7/1/19)
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. More >

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'
Source: Streetwise Reports  (7/1/19)
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. More >

Biotech's Data Well Received at Neurodegenerative Diseases Symposium
Source: Streetwise Reports  (6/28/19)
The company shared findings from its lead clinical program, in Alzheimer's disease. More >

Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever
Source: Streetwise Reports  (6/28/19)
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. More >

Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval
Source: Streetwise Reports  (6/27/19)
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. More >

Strategic Partnership Highlights Global Ambitions for NASH Therapy
Source: Streetwise Reports  (6/26/19)
The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. More >

Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership
Source: Streetwise Reports  (6/26/19)
The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. More >

Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board
Source: Streetwise Reports  (6/22/19)
The expert brings to the board a deep knowledge of neurodegeneration. More >

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study
Source: Streetwise Reports  (6/19/19)
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. More >

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study
Source: Streetwise Reports  (6/19/19)
The highlights of the results were presented in an H.C. Wainwright & Co. report. More >

Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis
Source: Streetwise Reports  (6/19/19)
The company received approval to proceed with the next and final dose level. More >

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'
Source: Streetwise Reports  (6/11/19)
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. More >

Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium
Source: Streetwise Reports  (6/8/19)
The focus will be the Canadian company's lead monoclonal antibody candidate. More >

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic
Source: Streetwise Reports  (6/5/19)
An explanation of the categorization and its implications are provided in a Paradigm Capital report. More >

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'
Source: Streetwise Reports  (6/5/19)
The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. More >

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'
Source: Streetwise Reports  (5/28/19)
The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. More >

Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease
Source: Streetwise Reports  (5/28/19)
The Canadian company's approach to this indication is now twofold. More >

California-Based Biopharma Signs Licensing Deal for Acquired Asset
Source: Streetwise Reports  (5/25/19)
The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. More >